Skip to main content

Table 1 Sample sizes, stratified by analysis and cancer type

From: The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study

Sample definition Breast (Women only) Prostate (Men only) Colorectal Lung
Available survey responses 700 454 1154 1154
Eligible survey responsesa 649 388 1082 1080
2 W linear regressionb 576 354 969 966
6 M linear regressionc 565 343 947 945
Longitudinal analysisd 500 314 847 844
  1. 2 W 2-week follow-up, 6 M 6-month follow-up
  2. aNo missing data for cancer-specific genetic risk result or baseline perceived risk; no reported cancer-specific diagnosis during data collection period
  3. bEligible survey responses, with available data for 2 W perceived risk
  4. cEligible survey responses, with available data for 6 M perceived risk
  5. dEligible survey responses, with available data for both 2 W and 6 M perceived risk